Lv3
250 积分 2023-09-12 加入
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
1天前
待确认
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
7天前
已完结
Real-world outcomes of pyrotinib-based therapy for HER2-positive breast cancer with brain metastases: A multicentre, retrospective analysis
2个月前
已完结
Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study
2个月前
已完结
皖公网安备34019202002308
